NCBI . NLM . NIH . GOV {}

Matching Content Categories {📚}

• Science
• Education
• Health & Fitness

Content Management System {📝}

What CMS is ncbi.nlm.nih.gov built with?

Custom-built

No common CMS systems were detected on Ncbi.nlm.nih.gov, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of ncbi.nlm.nih.gov audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Ncbi.nlm.nih.gov Make Money? {💸}

We see no obvious way the site makes money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Ncbi.nlm.nih.gov has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

patients, doi, cancer, van, ret, tumor, clinical, study, therapy, molecular, scholar, cell, pubmed, google, tumors, therapeutics, pmc, drug, combination, patient, signaling, aberrations, supplementary, solid, article, mtor, inhibitors, kinase, free, response, targets, activity, receptor, resistance, number, dose, figure, pharmaceuticals, studies, pathways, trial, shown, toxicities, pathway, table, everolimus, phase, experienced, harboring, novartis,

Topics {✒️}

pi3k/akt/mtor signaling pathways compare interval-scaled variables wilcoxon rank-sum test multi-tyrosine kinase inhibitor pi3k-dependent feedback loop maximum anti-nausea regimens pmc beta search advanced/refractory solid malignancies advanced/refractory solid tumors small-cell lung cancer median progression-free survival hgf/c-met pathway grant number 133835-csdg-19-153-01-pcsm multi-targeted rtk inhibitors ret-driven preclinical models chao physician-scientist pi3k/akt/mtor inhibitors oral fda-approved agents salivary duct carcinoma pi3k/akt/mtor pathway dual pi3k/mtor inhibitors consultant/advisory board member primary oncogenic signal targeting ret-driven cancers receptor tyrosine kinases inhibits downstream signaling b-cell lymphoma khalifa scholars award publisher site pdf research funding/grant support dose-escalation study demonstrated cell-based studies suggest investigator-initiated nonrandomized multikinase ret inhibitor common g3-g4 toxicities advanced solid cancers rutgers cancer institute egf receptor signaling small molecule inhibitor current fda-approved dose downstream signaling pathways nat rev cancer license information pmcid advanced solid tumors akt signaling pathways required dose modifications guide future investigations pi3k/akt pathways renal cell carcinoma inhibiting ret signaling

Questions {❓}

• Dual PI3K/mTOR inhibitors: does p53 modulate response?

Social Networks {👍}(6)

• https://twitter.com/ncbi
• https://www.facebook.com/ncbi.nlm
• https://www.linkedin.com/company/ncbinlm
• https://twitter.com/nlm_nih
• https://www.facebook.com/nationallibraryofmedicine
• https://www.youtube.com/user/NLMNIH

External Links {🔗}(80)

• What is the earnings of https://doi.org/10.1016/j.esmoop.2021.100079?
• Explore the financials of http://ClinicalTrials.gov
• How much profit is https://clinicaltrials.gov/ct2/show/NCT01582191 making per month?
• Learn how profitable https://doi.org/10.1016/j.cell.2010.06.011 is on a monthly basis
• What's the profit of https://scholar.google.com/scholar_lookup?journal=Cell&title=Cell%20signaling%20by%20receptor%20tyrosine%20kinases&author=M.A.%20Lemmon&author=J.%20Schlessinger&volume=141&issue=7&publication_year=2010&pages=1117-1134&pmid=20602996&doi=10.1016/j.cell.2010.06.011&?
• Discover the revenue of https://doi.org/10.1038/35077225
• How much does https://scholar.google.com/scholar_lookup?journal=Nature&title=Oncogenic%20kinase%20signalling&author=P.%20Blume-Jensen&author=T.%20Hunter&volume=411&issue=6835&publication_year=2001&pages=355-365&pmid=11357143&doi=10.1038/35077225& make?
• How much does https://doi.org/10.1038/nrc1360 pull in monthly?
• What's the monthly money flow for https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer&title=The%20discovery%20of%20receptor%20tyrosine%20kinases:%20targets%20for%20cancer%20therapy&author=A.%20Gschwind&author=O.M.%20Fischer&author=A.%20Ullrich&volume=4&issue=5&publication_year=2004&pages=361-370&pmid=15122207&doi=10.1038/nrc1360&?
• What's the profit of https://doi.org/10.1038/nrclinonc.2014.104?
• What's the financial intake of https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin%20Oncol&title=Acquired%20resistance%20to%20TKIs%20in%20solid%20tumours:%20learning%20from%20lung%20cancer&author=D.R.%20Camidge&author=W.%20Pao&author=L.V.%20Sequist&volume=11&issue=8&publication_year=2014&pages=473-481&pmid=24981256&doi=10.1038/nrclinonc.2014.104&?
• https://doi.org/10.1093/annonc/mdx703's revenue stream
• What's the profit of https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&title=Mechanisms%20of%20acquired%20resistance%20to%20first-%20and%20second-generation%20EGFR%20tyrosine%20kinase%20inhibitors&author=D.%20Westover&author=J.%20Zugazagoitia&author=B.C.%20Cho&author=C.M.%20Lovly&author=L.%20Paz-Ares&volume=29&issue=suppl%201&publication_year=2018&pages=i10-i19&pmid=29462254&doi=10.1093/annonc/mdx703&?
• How much revenue does https://doi.org/10.1158/1078-0432.CCR-13-1610 bring in?
• What are the earnings of https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=Molecular%20pathways:%20resistance%20to%20kinase%20inhibitors%20and%20implications%20for%20therapeutic%20strategies&author=C.M.%20Lovly&author=A.T.%20Shaw&volume=20&issue=9&publication_year=2014&pages=2249-2256&pmid=24789032&doi=10.1158/1078-0432.CCR-13-1610&?
• https://doi.org/10.1038/nrclinonc.2012.245 income
• How profitable is https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin%20Oncol&title=Safety%20and%20feasibility%20of%20targeted%20agent%20combinations%20in%20solid%20tumours&author=S.R.%20Park&author=M.%20Davis&author=J.H.%20Doroshow&author=S.%20Kummar&volume=10&issue=3&publication_year=2013&pages=154-168&pmid=23358316&doi=10.1038/nrclinonc.2012.245&?
• What's the income generated by https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&title=ZD6474,%20an%20orally%20available%20inhibitor%20of%20KDR%20tyrosine%20kinase%20activity,%20efficiently%20blocks%20oncogenic%20RET%20kinases&author=F.%20Carlomagno&author=D.%20Vitagliano&author=T.%20Guida&volume=62&issue=24&publication_year=2002&pages=7284-7290&pmid=12499271& each month?
• Learn about the earnings of https://doi.org/10.1038/nrc3680
• Find out how much https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer&title=RET%20revisited:%20expanding%20the%20oncogenic%20portfolio&author=L.M.%20Mulligan&volume=14&issue=3&publication_year=2014&pages=173-186&pmid=24561444&doi=10.1038/nrc3680& earns monthly
• See how much https://doi.org/10.1097/00001813-200606000-00001 makes per month
• What's the financial gain of https://scholar.google.com/scholar_lookup?journal=Anticancer%20Drugs&title=Recent%20developments%20in%20targeting%20the%20mammalian%20target%20of%20rapamycin%20(mTOR)%20kinase%20pathway&author=P.%20Smolewski&volume=17&issue=5&publication_year=2006&pages=487-494&pmid=16702804&doi=10.1097/00001813-200606000-00001&?
• How much does https://doi.org/10.1016/j.celrep.2013.12.035 pull in?
• Revenue of https://scholar.google.com/scholar_lookup?journal=Cell%20Rep&title=Assessing%20PIK3CA%20and%20PTEN%20in%20early-phase%20trials%20with%20PI3K/AKT/mTOR%20inhibitors&author=F.%20Janku&author=D.S.%20Hong&author=S.%20Fu&volume=6&issue=2&publication_year=2014&pages=377-387&pmid=24440717&doi=10.1016/j.celrep.2013.12.035&
• Learn about the earnings of https://doi.org/10.1200/JCO.2011.36.1196
• Learn about the earnings of https://scholar.google.com/scholar_lookup?journal=J%C2%A0Clin%20Oncol&title=PI3K/AKT/mTOR%20inhibitors%20in%20patients%20with%20breast%20and%20gynecologic%20malignancies%20harboring%20PIK3CA%20mutations&author=F.%20Janku&author=J.J.%20Wheler&author=S.N.%20Westin&volume=30&issue=8&publication_year=2012&pages=777-782&pmid=22271473&doi=10.1200/JCO.2011.36.1196&
• What's the financial gain of https://doi.org/10.1158/0008-5472.CAN-05-2925?
• Learn about the earnings of https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&title=mTOR%20inhibition%20induces%20upstream%20receptor%20tyrosine%20kinase%20signaling%20and%20activates%20Akt&author=K.E.%20O'Reilly&author=F.%20Rojo&author=Q.B.%20She&volume=66&issue=3&publication_year=2006&pages=1500-1508&pmid=16452206&doi=10.1158/0008-5472.CAN-05-2925&
• Learn about the earnings of https://doi.org/10.1172/JCI34739
• What's https://scholar.google.com/scholar_lookup?journal=J%C2%A0Clin%20Invest&title=Inhibition%20of%20mTORC1%20leads%20to%20MAPK%20pathway%20activation%20through%20a%20PI3K-dependent%20feedback%20loop%20in%20human%20cancer&author=A.%20Carracedo&author=L.%20Ma&author=J.%20Teruya-Feldstein&volume=118&issue=9&publication_year=2008&pages=3065-3074&pmid=18725988&doi=10.1172/JCI34739&'s gross income?
• How much cash flow does https://doi.org/10.1530/ERC-13-0085 have monthly?
• Earnings of https://scholar.google.com/scholar_lookup?journal=Endocr%20Relat%20Cancer&title=Targeting%20mTOR%20in%20RET%20mutant%20medullary%20and%20differentiated%20thyroid%20cancer%20cells&author=M.L.%20Gild&author=I.%20Landa&author=M.%20Ryder&author=R.A.%20Ghossein&author=J.A.%20Knauf&volume=20&issue=5&publication_year=2013&pages=659-667&pmid=23828865&doi=10.1530/ERC-13-0085&
• What's the income of https://doi.org/10.1016/S1470-2045(15)00290-9?
• What are the earnings of https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&title=Lenvatinib,%20everolimus,%20and%20the%20combination%20in%20patients%20with%20metastatic%20renal%20cell%20carcinoma:%20a%20randomised,%20phase%202,%20open-label,%20multicentre%20trial&author=R.J.%20Motzer&author=T.E.%20Hutson&author=H.%20Glen&volume=16&issue=15&publication_year=2015&pages=1473-1482&pmid=26482279&doi=10.1016/S1470-2045(15)00290-9&?
• Monthly income for https://doi.org/10.1016/j.ejca.2008.10.026
• How much does https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&title=New%20response%20evaluation%20criteria%20in%20solid%20tumours:%20revised%20RECIST%20guideline%20(version%201.1)&author=E.A.%20Eisenhauer&author=P.%20Therasse&author=J.%20Bogaerts&volume=45&issue=2&publication_year=2009&pages=228-247&pmid=19097774&doi=10.1016/j.ejca.2008.10.026& make?
• What's the financial outcome of https://doi.org/10.1016/j.ccr.2005.09.005?
• How much does https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&title=Drug%20resistance%20by%20evasion%20of%20antiangiogenic%20targeting%20of%20VEGF%20signaling%20in%20late-stage%20pancreatic%20islet%20tumors&author=O.%20Casanovas&author=D.J.%20Hicklin&author=G.%20Bergers&author=D.%20Hanahan&volume=8&issue=4&publication_year=2005&pages=299-309&pmid=16226705&doi=10.1016/j.ccr.2005.09.005& generate monthly?
• How much profit is https://doi.org/10.1172/JCI42405 making per month?
• Discover the revenue of https://scholar.google.com/scholar_lookup?journal=J%C2%A0Clin%20Invest&title=Upregulated%20stromal%20EGFR%20and%20vascular%20remodeling%20in%20mouse%20xenograft%20models%20of%20angiogenesis%20inhibitor-resistant%20human%20lung%20adenocarcinoma&author=T.%20Cascone&author=M.H.%20Herynk&author=L.%20Xu&volume=121&issue=4&publication_year=2011&pages=1313-1328&pmid=21436589&doi=10.1172/JCI42405&
• How much does https://doi.org/10.1038/nature11183 pull in monthly?
• What's the monthly money flow for https://scholar.google.com/scholar_lookup?journal=Nature&title=Tumour%20micro-environment%20elicits%20innate%20resistance%20to%20RAF%20inhibitors%20through%20HGF%20secretion&author=R.%20Straussman&author=T.%20Morikawa&author=K.%20Shee&volume=487&issue=7408&publication_year=2012&pages=500-504&pmid=22763439&doi=10.1038/nature11183&?
• See how much https://doi.org/10.1158/1078-0432.CCR-16-3216 makes per month
• How much does https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=The%20HGF/c-MET%20pathway%20is%20a%20driver%20and%20biomarker%20of%20VEGFR-inhibitor%20resistance%20and%20vascular%20remodeling%20in%20non-small%20cell%20lung%20cancer&author=T.%20Cascone&author=L.%20Xu&author=H.Y.%20Lin&volume=23&issue=18&publication_year=2017&pages=5489-5501&pmid=28559461&doi=10.1158/1078-0432.CCR-16-3216& gross monthly?
• What's the financial outcome of https://doi.org/10.1158/2159-8290.CD-13-0353?
• What's the income generated by https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&title=Activating%20mTOR%20mutations%20in%20a%20patient%20with%20an%20extraordinary%20response%20on%20a%20phase%20I%20trial%20of%20everolimus%20and%20pazopanib&author=N.%20Wagle&author=B.C.%20Grabiner&author=E.M.%20Van%20Allen&volume=4&issue=5&publication_year=2014&pages=546-553&pmid=24625776&doi=10.1158/2159-8290.CD-13-0353& each month?
• Check the income stats for https://doi.org/10.1016/j.ejca.2017.07.031
• Discover the revenue of https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&title=Phase%20I%20study%20of%20axitinib%20and%C2%A0everolimus%20in%20metastatic%20solid%20tumours%20and%20extension%20to%20metastatic%20renal%20cell%20carcinoma:%20results%20of%20EVAX%20study&author=A.%20Ravaud&author=C.%20Gomez-Roca&author=M.Q.%20Picat&volume=85&publication_year=2017&pages=39-48&pmid=28886476&doi=10.1016/j.ejca.2017.07.031&
• Financial intake of https://doi.org/10.1038/sj.bjc.6604269
• Get to know https://scholar.google.com/scholar_lookup?journal=Br%20J%20Cancer&title=Inhibition%20of%20mTOR%20pathway%20by%C2%A0everolimus%20cooperates%20with%20EGFR%20inhibitors%20in%20human%20tumours%20sensitive%20and%20resistant%20to%20anti-EGFR%20drugs&author=R.%20Bianco&author=S.%20Garofalo&author=R.%20Rosa&volume=98&issue=5&publication_year=2008&pages=923-930&pmid=18319715&doi=10.1038/sj.bjc.6604269&'s earnings
• Financial intake of https://doi.org/10.1093/annonc/mdi247
• How much income is https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&title=Clinical%20evaluation%20of%20ZD6474,%20an%20orally%20active%20inhibitor%20of%20VEGF%20and%20EGF%20receptor%20signaling,%20in%20patients%20with%20solid,%20malignant%20tumors&author=S.N.%20Holden&author=S.G.%20Eckhardt&author=R.%20Basser&volume=16&issue=8&publication_year=2005&pages=1391-1397&pmid=15905307&doi=10.1093/annonc/mdi247& earning monthly?
• What are the total earnings of https://doi.org/10.1158/1078-0432.CCR-14-1998?
• Explore the financials of https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=A%C2%A0translational,%20pharmacodynamic,%20and%20pharmacokinetic%20phase%20IB%20clinical%20study%20of%20everolimus%20in%20resectable%20non-small%20cell%20lung%20cancer&author=T.K.%20Owonikoko&author=S.S.%20Ramalingam&author=D.L.%20Miller&volume=21&issue=8&publication_year=2015&pages=1859-1868&pmid=25673697&doi=10.1158/1078-0432.CCR-14-1998&
• How much revenue does https://doi.org/10.1634/theoncologist.2016-0079 generate?
• How much does https://scholar.google.com/scholar_lookup?journal=Oncologist&title=Sarcomas%20associated%20with%20genetic%20cancer%20predisposition%20syndromes:%20a%20review&author=M.%20Farid&author=J.%20Ngeow&volume=21&issue=8&publication_year=2016&pages=1002-1013&pmid=27401891&doi=10.1634/theoncologist.2016-0079& pull in monthly?
• How much does https://doi.org/10.1158/1078-0432.CCR-13-1291 gross monthly?
• Get to know what's the income of https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=Dual%20PI3K/mTOR%20inhibitors:%20does%20p53%20modulate%20response?&author=O.%20Ekshyyan&author=A.%20Anandharaj&author=C.-A.%20Nathan&volume=19&issue=14&publication_year=2013&pages=3719-3721&pmid=23741068&doi=10.1158/1078-0432.CCR-13-1291&
• Profit of https://doi.org/10.1038/leu.2015.81
• How much cash flow does https://scholar.google.com/scholar_lookup?journal=Leukemia&title=Next-generation%20sequencing%20reveals%20clinically%20actionable%20molecular%20markers%20in%20myeloid%20sarcoma&author=Z.%20Li&author=F.%20Stolzel&author=K.%20Onel&volume=29&issue=10&publication_year=2015&pages=2113-2116&pmid=25787914&doi=10.1038/leu.2015.81& have monthly?
• How much income does https://doi.org/10.1158/1078-0432.CCR-11-0379 have?
• What is the earnings of https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=Novel%20functional%20germline%20variants%20in%20the%20VEGF%20receptor%202%20gene%20and%20their%20effect%20on%20gene%20expression%20and%20microvessel%20density%20in%20lung%20cancer&author=D.M.%20Glubb&author=E.%20Cerri&author=A.%20Giese&volume=17&issue=16&publication_year=2011&pages=5257-5267&pmid=21712447&doi=10.1158/1078-0432.CCR-11-0379&?
• Find out how much https://doi.org/10.1038/nrclinonc.2017.175 earns monthly
• https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin%20Oncol&title=Targeting%20RET-driven%20cancers:%20lessons%20from%20evolving%20preclinical%20and%20clinical%20landscapes&author=A.%20Drilon&author=Z.I.%20Hu&author=G.G.Y.%20Lai&author=D.S.W.%20Tan&volume=15&issue=3&publication_year=2018&pages=151-167&pmid=29134959&doi=10.1038/nrclinonc.2017.175&'s revenue stream
• How much income is https://doi.org/10.1158/2159-8290.CD-18-0338 earning monthly?
• What's the revenue for https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&title=Precision%20targeted%20therapy%20with%20BLU-667%20for%20RET-driven%20cancers&author=V.%20Subbiah&author=J.F.%20Gainor&author=R.%20Rahal&volume=8&issue=7&publication_year=2018&pages=836-849&pmid=29657135&doi=10.1158/2159-8290.CD-18-0338&?
• What's the financial gain of https://doi.org/10.1093/annonc/mdy137?
• What's the total monthly financial gain of https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&title=Selective%20RET%20kinase%20inhibition%20for%20patients%20with%20RET-altered%20cancers&author=V.%20Subbiah&author=V.%20Velcheti&author=B.B.%20Tuch&volume=29&issue=8&publication_year=2018&pages=1869-1876&pmid=29912274&doi=10.1093/annonc/mdy137&?
• Financial intake of https://github.com/ncbi
• Check the income stats for https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508, -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508! 4d-77.0988323
• How much does https://www.nlm.nih.gov/web_policies.html earn?
• How much does https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office rake in every month?
• How much does https://www.hhs.gov/vulnerability-disclosure-policy/index.html net monthly?
• Get to know https://support.nlm.nih.gov/?pagename=cloudpmc-viewer%3Apmc%3Aarticle%3Ajournal's earnings
• How much income is https://www.nlm.nih.gov/accessibility.html earning monthly?
• What's the financial outcome of https://www.nlm.nih.gov/careers/careers.html?
• What are the earnings of https://www.nlm.nih.gov/?
• See how much https://www.nih.gov/ makes per month
• Learn about the earnings of https://www.hhs.gov/
• How profitable is https://www.usa.gov/?

Analytics and Tracking {📊}

• Google Analytics
• Google Analytics 4
• Google Tag Manager

Libraries {📚}

• jQuery
• jQuery module (jquery-3.6.0)
• Zoom.js

Emails and Hosting {✉️}

Mail Servers:

• nihcesxway.hub.nih.gov
• nihcesxway2.hub.nih.gov
• nihcesxway3.hub.nih.gov
• nihcesxway4.hub.nih.gov
• nihcesxway5.hub.nih.gov

Name Servers:

• dns1-ncbi.ncbi.nlm.nih.gov
• dns2-ncbi.ncbi.nlm.nih.gov
• lhcns1.nlm.nih.gov
• lhcns2.nlm.nih.gov

CDN Services {📦}

• Ncbi